Welcome to our X-Europe startup interview series. We have virtually sat down with a number of our founders from past cohorts to hear all about their solutions, vision for the future, and what made them tick during our X Europe programme. So whether you are a deep tech founder looking for startup support, an eagle-eyed investor, or simply interested in the possibilities that technology can bring to society, then we welcome you to take a read. Please meet RTsafe, the first FDA cleared, personalized solution that minimizes the risk of severe side-effects induced by radiation therapy to brain cancer patients.
Can you briefly explain what your solution is all about? What’s unique about it?
RTsafe develops PseudoPatient®; the first FDA cleared, personalized solution that minimizes the risk of severe side-effects induced by radiation therapy to brain cancer patients.
How can your solution impact the Health sector?
Four million patients per year can have their treatment simulated on a real replica of their head and brain before they undergo their actual treatment. Nine thousand Radiation Oncology Clinics can enhance outcomes in terms of efficacy and safety.
Since the foundation of your company, what has been its biggest milestones? What challenges are you still trying to overcome?
PseudoPatient® is fully patented worldwide, ISO13485 certified, and well perceived by the scientific society, as more than 70 scientific publications prove. We have gained awards from MIT, Seal of Excellence from Horizon2020, indicating that we deserve to be funded, and so on. We have achieved €1.3M cumulative revenues and we have built a distribution network covering 21 countries. We are still trying to achieve our reimbursement strategy goals and our targeted growth.
What was the status of your product before joining X-Europe? How has your original product vision evolved?
Actually, our product status was similar to the current before joining X-Europe but we have improved the way we communicate our investment strategy.
After joining and benefiting from the services X-Europe has provided to you, what next steps do you envision?
To implement our robust business plan post-funding.
What tips do you have for entrepreneurs trying to succeed in the HealthTech/BioTech field?
Patent, regulatory compliance, go to market strategy definition.
What’s unique about the X-Europe programme?
Networking.
--------------------------------------------------------------------------------
Comments